Why Alvotech stock moves
Alvotech rose clearly, while the market fell clearly.
Written after the close on ·
Updated 08:00 with news that came after the close
Why today
16,307 news analyzed todayAlvotech rose clearly, while the market fell clearly.
The only company news from that session was an earnings preview, which notes the report is due post-market on November 11, so it is not the reason for the move.
No company news explains the rise.
Over the last five trading days, the shares were roughly unchanged, in line with the market.
Earnings are due Wednesday November 11, after the US market close, with a webcast on November 12.
Today's move of +3.70% was 1.6 times a normal day's 2.2%. OMX Stockholm 30 moved −1.01% on the same day.
Alvotech +3.70%OMX Stockholm 30 −1.01%Against the market
What analysts expect, and how often they have been right
Analysts’ estimates for Alvotech.
Ratings
Price targets
Latest price 47.70 SEK
What the key figures say about Alvotech
The figures connect what Alvotech earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -$2.60–$0.10. Peers: BioGaia 3.87 SEK, Hims & Hers Health -$0.64, Lundbeck 3.92 DKK.
What the company sold during the year.
2022–2025: $83.0M–$586M. Peers: BioGaia 1.7 bn SEK, Hims & Hers Health $2.6B, Lundbeck 26.0 bn DKK. 2026 estimate: $653M ($647M–$659M). 2027 estimate: $786M ($725M–$901M).
The percentage of revenue left after the costs of running the business.
2022–2025: −417.3%–14.2%. Peers: BioGaia 29.4%, Hims & Hers Health −6.0%, Lundbeck 21.8%.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: 4.10–4.10. Peers: BioGaia -1.07, Lundbeck 0.87.
More key figures
Cash left after investments, divided by the number of shares.
2022–2025: -$1.45–-$0.47. Peers: BioGaia 2.55 SEK, Hims & Hers Health $0.26, Lundbeck 5.20 DKK.
The percentage of assets financed by shareholders’ equity.
2022–2025: −98.1%–−19.1%.
What to watch next, and why
The earnings report shows how Alvotech's revenue and profit have changed.
- Earnings report
The earnings report shows how Alvotech's revenue and profit have changed.
Add to calendar
Earnings report
Next report: · Add to calendar · Google Calendar
+8.66% −8.03% −2.13% −0.04%
10,000 SEK in Alvotech bought on May 19, 2025 is worth 4,850 SEK today, with dividends reinvested.
The same amount in OMX Stockholm 30 with dividends would have become 13,100 SEK.
What would 10,000 SEK in Alvotech be worth today? →
What would 10,000 SEK in Alvotech be worth today?
4,850 SEK
with dividends reinvested, bought on May 19, 2025. The same amount in OMX Stockholm 30 with dividends would have become 13,100 SEK.
At worst it was worth 2,830 SEK (June 3, 2026).
The five biggest days of the journey
· +34.5% · the whole market rose 1.4% the same day
· −31.2% · the whole market fell 0.4% the same day
· +19.9% · the whole market was unchanged the same day
· +17.9% · the whole market was unchanged the same day
· −13.3% · the whole market rose 2.6% the same day
Earlier days
−0.62% market −0.11% Alvotech was roughly unchanged over the week, while the OMX Stockholm 30 index was also roughly flat. Read →
Alvotech was roughly unchanged over the week, while the OMX Stockholm 30 index was also roughly flat.
The shares rose clearly in the last session, moving against a market that fell clearly that day.
The week's company news was mostly scheduling: investor conference appearances and the date of the Q3 2026 results.
Those notices alone do not explain a price move.
+3.72% market −0.32% Alvotech rose clearly, without company news. Read →
Alvotech rose clearly, without company news.
The market fell slightly that day, so the stock moved against it.
Over the last five trading days, Alvotech fell clearly while the market rose slightly.
The most likely reason for the weak week is not in the news.
Trading was about three times its usual level, so the rise drew heavy interest.
−3.80% market +0.83% Alvotech fell sharply without company news explaining the. Read →
Alvotech fell sharply without company news explaining the.
Over the last five trading days Alvotech fell sharply, against a slightly rising market.
In the last session the shares fell clearly while the OMX Stockholm 30 rose clearly.
No company news from that session explains the drop.
The five-day move was big for Alvotech, and short positions rose slightly in late October, a background factor rather than a proven cause.
+0.33% market −0.08% Alvotech was roughly unchanged, an ordinary day. Read →
Alvotech was roughly unchanged, an ordinary day.
Over the same session OMX Stockholm 30 was roughly flat, so the stock moved in line with the market.
Over the last five trading days Alvotech was roughly unchanged while the market rose slightly, so it lagged the index.
Company news in the session was a statement that management aims for revenue growth in the second half of 2026, and a commentary piece on its factory.
Alvotech will report nine-month results on Wednesday 11 November 2026, after the US market close.
−4.27% market +0.48% Alvotech fell sharply without a company-news explanation. Read →
Alvotech fell sharply without a company-news explanation.
Over the same days, OMX Stockholm 30 rose slightly, so Alvotech moved against the market.
Over the last five trading days, Alvotech was roughly unchanged while the market rose clearly.
The day's news was about investor conference appearances in November, which usually do not move a share price much on their own.
The next earnings report comes on 11 November 2026, which is worth watching.
+4.23% market +3.01% Alvotech rose slightly over the week, moving in line with the OMX Stockholm 30 index, which rose clearly. Read →
Alvotech rose slightly over the week, moving in line with the OMX Stockholm 30 index, which rose clearly.
The most recent session saw a clear fall, moving more than the market, which dipped slightly.
The FDA approved a new manufacturing process for Simlandi on Tuesday 20 October, which doubles output per batch and freed capacity, a development that likely supported the shares earlier in the week.
On Wednesday 28 October the company announced it will report nine-month and third-quarter results on Wednesday 11 November, after the US market close.
+6.49% market +0.33% Alvotech rose, moving well ahead of the market. Read →
Alvotech rose, moving well ahead of the market.
Company news from that session was an announcement of its Q3 2026 results date.
Such notices contain no new figures and rarely explain a big move on their own.
Over the last five trading days the stock fell slightly while OMX Stockholm 30 rose slightly.
Earlier that week, FDA approval of a new Simlandi manufacturing process likely supported the shares.
−1.09% market +1.57% Alvotech fell slightly. Read →
Alvotech fell slightly.
No company news from that session explains the move, and the session was an ordinary day for Alvotech.
Over the last five trading days, Alvotech fell clearly, more than the market, which fell slightly.
That week's fall is a big move for Alvotech, rare in the past year.
The stock is well below its highest close of the past year, which came in late October last year.
−6.40% market +0.41% Alvotech fell sharply, moving against a market that rose slightly, with no company news explaining it. Read →
Alvotech fell sharply, moving against a market that rose slightly, with no company news explaining it.
Over the last five trading days, Alvotech fell clearly and moved more than OMX Stockholm 30, which fell sharply.
Trading was about twice a normal session, so the drop came on heavy activity.
The stock sits well below its highest close of the past year but well above its lowest, so this is a pullback within a wide range.
Recent news was mostly positive, including an FDA approval on Tuesday and a European filing on Wednesday, but a research firm cut its rating to strong sell on Thursday.
−8.27% market −3.67% Alvotech fell clearly over the last five trading days, more than the wider market, which also fell. Read →
Alvotech fell clearly over the last five trading days, more than the wider market, which also fell.
The drop came despite a Tuesday rally on an FDA approval for a faster Simlandi manufacturing process, which lifted the shares for a time.
Trading was heavy, about twice normal, and the sell-off likely reflected a downgrade to strong sell by a research house on Thursday.
The next earnings report is due on 11 November, which is worth watching.
−3.72% market −2.51% Alvotech fell clearly, moving in line with the Stockholm market, which also fell sharply. Read →
Alvotech fell clearly, moving in line with the Stockholm market, which also fell sharply.
The biggest company item from that day was a research firm cutting its rating to strong sell, a recommendation to avoid the shares.
Over the last five trading days Alvotech fell clearly, more than the market, which also fell clearly.
Earlier this week, the stock had risen after an FDA approval for a new Simlandi manufacturing process.
The shares are well below their high of late last October, but well above their low of early June.
+2.99% market −0.89% Alvotech rose clearly, against a falling market. Read →
Alvotech rose clearly, against a falling market.
Over the last five trading days, the shares fell slightly, a little more than the market.
Trading volume was about four times a normal session.
The next earnings report is on 11 November 2026.
−3.83% market +1.25% Alvotech fell clearly, and no company news explains the move. Read →
Alvotech fell clearly, and no company news explains the move.
Over the last five trading days, Alvotech fell sharply while OMX Stockholm 30 rose slightly, so it moved against the market.
That fall was a big move for Alvotech, roughly twice its usual five-day swing, and moves that size have been rare over the past year.
No company news from the last session was found.
The recent news came before that session, including a regulatory filing for a higher-dose Eylea copy and a long-term US manufacturing deal with LOTTE Biologics, but neither can be linked to the drop.
Learn more · Why do stocks move on earnings day? · Why do stocks go up and down?